anx
- Creatore Discussione osinod
- Data di Inizio
osinod
Banned
ADVENTRX Pharmaceuticals, Inc., (Adventrx) è una società di biopharmaceutical, impegna su in-autorizzazione, sviluppando e commercializzando primariamente candidati di prodotto per il trattamento di cancro e malattia infettiva. La Società si è concentrata primariamente su avanzare ANX-530 ed ANX-514 che sono formulazioni di emulsione di medicine di chemioterapia introdotte sul mercato. Sta sviluppando anche ANX-510, o CoFactor che è un biomodulator folate-basato progettò per sostituire
osinod
Banned
SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has granted Shin Poong Pharmaceutical Co., Ltd. (SEO: 019170.KS) exclusive rights in South Korea to make, use and sell ANX-514 (docetaxel emulsion), one of its two lead product candidates. Under the terms of their agreement, ADVENTRX will receive an upfront cash payment of $300,000, up to approximately $2 million in regulatory and commercial milestones and royalties on net sales of licensed products. Shin Poong is responsible for all development and commercial activities related to ANX-514 in South Korea.
Related Quotes
SymbolPriceChangeANX0.14-0.04
{"s" : "anx","k" : "c10,l10,p20,t10","o" : "","j" : ""}
ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere®, an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck and gastric cancers. In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion. The market for Taxotere in South Korea was in excess of $30 million in 2007.
"Shin Poong is well-positioned to successfully develop and commercialize ANX-514 in South Korea," stated Brian M. Culley, Chief Business Officer of ADVENTRX. "Established in 1962, Shin Poong has grown to more than 1,500 employees. They are a leader in this territory, with expertise in clinical development, as well as a dedicated business unit focused on the sales and marketing of oncology products."
"We are excited about this first validation of our detergent-free docetaxel program, and we remain committed to finding additional partners for ANX-514, as well as ANX-530, in other territories and working towards consummating the strategic transaction process we began in December 2008," added Mr. Culley. "With support from our consultants and vendors, we continue to be on track to announce preliminary pharmacokinetic results from our bioequivalence study of ANX-514 in the second quarter of 2009."
"We are delighted at the opportunity to work with ADVENTRX and foresee substantial market potential for ANX-514 in South Korea, an opportunity that we believe we are fully equipped to realize. We believe ANX-514 will secure a significant market share of the current $30 million docetaxel market in Korea, a market which is expected to grow to up to $50 million over the next several years," stated Mr. Byung Hwa Kim, Chief Executive Officer of Shin Poong.
About ANX-514 (docetaxel emulsion)
ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.
Related Quotes
SymbolPriceChangeANX0.14-0.04
{"s" : "anx","k" : "c10,l10,p20,t10","o" : "","j" : ""}
ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere®, an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck and gastric cancers. In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion. The market for Taxotere in South Korea was in excess of $30 million in 2007.
"Shin Poong is well-positioned to successfully develop and commercialize ANX-514 in South Korea," stated Brian M. Culley, Chief Business Officer of ADVENTRX. "Established in 1962, Shin Poong has grown to more than 1,500 employees. They are a leader in this territory, with expertise in clinical development, as well as a dedicated business unit focused on the sales and marketing of oncology products."
"We are excited about this first validation of our detergent-free docetaxel program, and we remain committed to finding additional partners for ANX-514, as well as ANX-530, in other territories and working towards consummating the strategic transaction process we began in December 2008," added Mr. Culley. "With support from our consultants and vendors, we continue to be on track to announce preliminary pharmacokinetic results from our bioequivalence study of ANX-514 in the second quarter of 2009."
"We are delighted at the opportunity to work with ADVENTRX and foresee substantial market potential for ANX-514 in South Korea, an opportunity that we believe we are fully equipped to realize. We believe ANX-514 will secure a significant market share of the current $30 million docetaxel market in Korea, a market which is expected to grow to up to $50 million over the next several years," stated Mr. Byung Hwa Kim, Chief Executive Officer of Shin Poong.
About ANX-514 (docetaxel emulsion)
ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.
osinod
Banned
SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has granted Shin Poong Pharmaceutical Co., Ltd. (SEO: 019170.KS) exclusive rights in South Korea to make, use and sell ANX-514 (docetaxel emulsion), one of its two lead product candidates.
SAN DIEGO, March 25 / PRNewswire-FirstCall / - ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) ha annunciato oggi che ha concesso Shin Poong Pharmaceutical Co., Ltd. (SEO: 019170.KS) i diritti esclusivi in Corea del Sud per realizzare, utilizzare e vendere ANX-514 (docetaxel emulsione), uno dei suoi due piombo prodotto candidati. Under the terms of their agreement, ADVENTRX will receive an upfront cash payment of $300,000, up to approximately $2 million in regulatory and commercial milestones and royalties on net sales of licensed products.
Secondo i termini del loro accordo, ADVENTRX riceverà un pagamento in contanti in anticipo di $ 300.000, fino a circa $ 2 milioni di regolamentazione e commerciale tappe e royalties sulle vendite nette dei prodotti in licenza. Shin Poong is responsible for all development and commercial activities related to ANX-514 in South Korea.
Shin Poong è responsabile di tutte le attività commerciali e di sviluppo legati alla ANX-514 in Corea del Sud. Related Quotes
Quotazioni correlati Symbol
Simbolo Price
Prezzo Change
Cambiare ANX
ANX 0.14
0,14 -0.04
-0,04 {"s" : "anx","k" : "c10,l10,p20,t10","o" : "","j" : ""}
( "s": "ANX", "k": "C10, L10, P20, T10", "O": "", "j": "") ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere®, an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck and gastric cancers.
ANX-514 è una riformulazione del blockbuster agenti chemioterapici, Taxotere ®, un agente anti-cancro che è approvato per il trattamento al seno, non a piccole cellule del polmone, della prostata, della testa e del collo e cancro gastrico. In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion.
Nel 2007, il mercato totale a livello mondiale per Taxotere in eccesso è stata di $ 3 miliardi. The market for Taxotere in South Korea was in excess of $30 million in 2007.
Il mercato dei Taxotere in Corea del Sud è al di sopra di $ 30 milioni nel 2007. "Shin Poong is well-positioned to successfully develop and commercialize ANX-514 in South Korea," stated Brian M. Culley, Chief Business Officer of ADVENTRX.
"Shin Poong è ben posizionata per sviluppare e commercializzare con successo ANX-514 in Corea del Sud", ha dichiarato Brian M. Culley, Chief Business Officer del ADVENTRX. "Established in 1962, Shin Poong has grown to more than 1,500 employees. They are a leader in this territory, with expertise in clinical development, as well as a dedicated business unit focused on the sales and marketing of oncology products."
"Fondata nel 1962, Shin Poong è cresciuto a più di 1.500 dipendenti. Si tratta di un leader in questo territorio, con esperienza in sviluppo clinico, così come una business unit dedicata concentrata sulla vendita e la commercializzazione di prodotti di oncologia". "We are excited about this first validation of our detergent-free docetaxel program, and we remain committed to finding additional partners for ANX-514, as well as ANX-530, in other territories and working towards consummating the strategic transaction process we began in December 2008," added Mr. Culley.
"Siamo entusiasti di questa prima convalida del nostro detergente priva di docetaxel programma, e noi rimaniamo impegnati alla ricerca di altri partner per ANX-514, così come ANX-530, in altri territori e di lavoro verso consumando il processo di transazione strategica abbiamo iniziato a dicembre 2008 ", ha aggiunto Mr. Culley. "With support from our consultants and vendors, we continue to be on track to announce preliminary pharmacokinetic results from our bioequivalence study of ANX-514 in the second quarter of 2009."
"Con il supporto dei nostri consulenti e fornitori, che continuano ad essere sulla buona strada per annunciare i risultati preliminari di farmacocinetica dal nostro studio di bioequivalenza ANX-514 nel secondo trimestre del 2009." "We are delighted at the opportunity to work with ADVENTRX and foresee substantial market potential for ANX-514 in South Korea, an opportunity that we believe we are fully equipped to realize. We believe ANX-514 will secure a significant market share of the current $30 million docetaxel market in Korea, a market which is expected to grow to up to $50 million over the next several years," stated Mr. Byung Hwa Kim, Chief Executive Officer of Shin Poong.
"Siamo lieti di l'opportunità di lavorare con ADVENTRX prevedono sostanziali e potenziale di mercato per ANX-514 in Corea del Sud, l'opportunità che riteniamo siano pienamente in grado di realizzare. Crediamo ANX-514 garantirà una significativa quota di mercato delle attuali $ 30 milioni di docetaxel in Corea del mercato, un mercato che dovrebbe crescere fino a $ 50 milioni nel corso dei prossimi anni ", ha dichiarato il Sig. Byung Hwa Kim, Chief Executive Officer di Shin Poong. About ANX -514 (docetaxel emulsion)
Chi ANX -514 (docetaxel emulsione) ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere.
ANX-514 è un nuovo nano-emulsione formulazione del farmaco chemioterapico docetaxel, una formulazione che è commercializzato con il marchio Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions.
ANX-514 è formulato senza polisorbato 80 o di altri detergenti ed è destinato a ridurre la gravità e / o incidenza di reazioni di ipersensibilità. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division.
Docetaxel è un agente antitumorale che agisce da perturbare il microtubular rete cellulare che è essenziale per la divisione cellulare. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions.
Immunosoppressori premedicazione docetaxel è consigliato per la terapia per ridurre l'incidenza e la gravità delle reazioni di ipersensibilità. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.
Docetaxel è approvato per il trattamento al seno, non a piccole cellule del polmone, della prostata, dello stomaco e di cancro della testa e del collo. About Shin Poong Pharmaceutical Co., Ltd.
Chi Shin Poong Pharmaceutical Co., Ltd. Shin Poong Pharmaceutical Company is a publicly traded company established in 1962 in Seoul, South Korea.
Shin Poong Pharmaceutical Company è una società stabilita nel 1962 a Seoul, Corea del Sud. It is one of the ten largest pharmaceutical companies in Korea with manufacturing operations in five countries, more than 1,500 employees world-wide, and sales in excess of US $200 million.
Si tratta di uno dei dieci più grandi aziende farmaceutiche in Corea con la produzione in cinque paesi, più di 1.500 dipendenti in tutto il mondo, e le vendite in eccesso di 200 milioni di US $. It is a top ranked marketer of pharmaceuticals in Korea and has a leading position in oncology through its Oncology Business Unit.
Si tratta di un alto posizionamento di marketing dei prodotti farmaceutici in Corea ed ha una posizione leader in oncologia attraverso la sua Business Unit Oncologia. Marketed products in oncology include Padexol Injection (paclitaxel), Didox Capsule (doxifluridine), OXP Injection (oxaliplatin) and CrabCan Injection (irrinotecan).
Prodotti commercializzati in oncologia iniezione comprendono Padexol (paclitaxel), Didox Capsule (doxifluridine), iniezione OXP (oxaliplatino) e iniezione CrabCan (irrinotecan). The company is collaborating with the World Health Organization on the development of a novel anti-malarial drug.
La società sta collaborando con l'Organizzazione Mondiale della Sanità per lo sviluppo di un nuovo farmaco anti-malarico. About ADVENTRX Pharmaceuticals
Chi ADVENTRX Farmaceutica ADVENTRX Pharmaceuticals is a biopharmaceutical company whose proprietary product candidates are designed to improve the safety and commercial potential of existing cancer treatments.
ADVENTRX Pharmaceuticals è un'azienda biofarmaceutica prodotto candidati la cui specialità sono progettati per migliorare la sicurezza e il potenziale commerciale degli attuali trattamenti contro il cancro. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets.
Nel dicembre 2008, la Società ha annunciato che sta valutando una serie di opzioni strategiche, compresa la vendita o la disposizione di uno o più dei suoi prodotti candidati programmi, un business strategico di concentrazione e le altre operazioni che massimizzano il valore dei beni della Società. In January and March 2009, the Company announced headcount reductions and cost containment measures to provide additional time to consummate a strategic transaction.
Nei mesi di gennaio e marzo 2009, la Società ha annunciato riduzioni di effettivi e di misure di contenimento dei costi al fine di fornire ulteriori consumato il tempo di uno strategico transazione. More information can be found on the Company's web site at www.adventrx.com .
Ulteriori informazioni possono essere trovate sul sito web della Società al www.adventrx.com. Forward Looking Statements
